NodThera Charts Obesity Future with First Patients Dosed in Phase 2 RESOLVE-1 Trial of Oral NLRP3 Inflammasome Inhibitor ...

The trial will initially involve healthy obese people receiving single and multiple escalating doses of the therapy.

Spago Nanomedical AB (publ) announced today that the Data Monitoring Committee (DMC) recommends the ongoing phase I/IIa study Tumorad-01 with the candidate drug 177Lu-SN201 to continue according to ...

Naggy took the child to a remote area on a trail near Loyalhanna Lake near Pittsburgh and made the girl ingest drugs. Cops ...

The first patient has received treatment with mavrostobart plus chemo in the phase 1/2 MORNINGSTAR trial for advanced solid ...

Vantage Biosciences has dosed the first subject in the randomised Phase II trial of oral therapy VX-01 to treat non-proliferative diabetic retinopathy (NPDR). The multi-centre, placebo-controlled ...

Investigators aim to establish an optimal dose and explore CER-1236's safety and preliminary anti-tumor activity.

Intellia reports a grade 4 liver enzyme elevation in a Nex-Z trial patient; no hospitalization is required, and enrollment ...

STORM Therapeutics, a clinical stage Cambridge company pioneering cellular reprogramming through RNA modifications to treat ...

Clinical trial to evaluate the safety and efficacy of YK012 in primary membranous nephropathy- Globally, this is the first bispecific CD19-directed ...

Authorities say John Umberger, 33, was one of several victims targeted by a group that lured and drugged victims to gain access to their bank accounts.